Identification of a catalytic residue of Clostridium paraputrificum N-acetyl-beta-D-glucosaminidase Nag3A by site-directed mutagenesis. 2006

Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
School of Medicine, Southern Yangtze University, Wuxi, China.

Clostridium paraputrificum M-21 beta-N-acetylglucosaminidase 3A (Nag3A) is an enzyme classified in family 3 of the glycoside hydrolases. To identify catalytic residues of this enzyme, mutations were introduced into highly conserved Glu and Asp residues. Replacement of Asp175 with Ala abolished the catalytic activity without change in the circular dichroism spectrum, strongly suggesting that this residue is a catalytic residue, a nucleophile/base or a proton donor. Since the K(m) values of mutant enzymes D119N, D229N, D229A and D274N increased 17 to 41 times as compared with that of wild-type enzyme, Asp119, Asp229, and Asp274 appear to be involved in substrate recognition and binding. Taking previous studies into consideration, we presume that Asp303 is the catalytic nucleophile and Asp175 is the proton donor of C. paraputrificum Nag3A.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D003013 Clostridium A genus of motile or nonmotile gram-positive bacteria of the family Clostridiaceae. Many species have been identified with some being pathogenic. They occur in water, soil, and in the intestinal tract of humans and lower animals.
D000118 Acetylglucosaminidase A beta-N-Acetylhexosaminidase that catalyzes the hydrolysis of terminal, non-reducing 2-acetamido-2-deoxy-beta-glucose residues in chitobiose and higher analogs as well as in glycoproteins. Has been used widely in structural studies on bacterial cell walls and in the study of diseases such as MUCOLIPIDOSIS and various inflammatory disorders of muscle and connective tissue. N-Acetyl-beta-D-glucosaminidase,Chitobiase,N,N-Diacetylchitobiase,N-Ac-beta-Glucosaminidase,NAGase,beta-D-Acetamido-2-Deoxyglucosidase,beta-D-N-acetylglucosaminidase,beta-N-Acetylglucosaminidase,N Ac beta Glucosaminidase,N Acetyl beta D glucosaminidase,N,N Diacetylchitobiase,beta D Acetamido 2 Deoxyglucosidase,beta D N acetylglucosaminidase,beta N Acetylglucosaminidase
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001224 Aspartic Acid One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. (+-)-Aspartic Acid,(R,S)-Aspartic Acid,Ammonium Aspartate,Aspartate,Aspartate Magnesium Hydrochloride,Aspartic Acid, Ammonium Salt,Aspartic Acid, Calcium Salt,Aspartic Acid, Dipotassium Salt,Aspartic Acid, Disodium Salt,Aspartic Acid, Hydrobromide,Aspartic Acid, Hydrochloride,Aspartic Acid, Magnesium (1:1) Salt, Hydrochloride, Trihydrate,Aspartic Acid, Magnesium (2:1) Salt,Aspartic Acid, Magnesium-Potassium (2:1:2) Salt,Aspartic Acid, Monopotassium Salt,Aspartic Acid, Monosodium Salt,Aspartic Acid, Potassium Salt,Aspartic Acid, Sodium Salt,Calcium Aspartate,Dipotassium Aspartate,Disodium Aspartate,L-Aspartate,L-Aspartic Acid,Magnesiocard,Magnesium Aspartate,Mg-5-Longoral,Monopotassium Aspartate,Monosodium Aspartate,Potassium Aspartate,Sodium Aspartate,Aspartate, Ammonium,Aspartate, Calcium,Aspartate, Dipotassium,Aspartate, Disodium,Aspartate, Magnesium,Aspartate, Monopotassium,Aspartate, Monosodium,Aspartate, Potassium,Aspartate, Sodium,L Aspartate,L Aspartic Acid
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses

Related Publications

Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
May 1995, Nihon rinsho. Japanese journal of clinical medicine,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
January 1998, Nihon rinsho. Japanese journal of clinical medicine,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
January 1999, The Journal of biological chemistry,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
February 1995, Nihon rinsho. Japanese journal of clinical medicine,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
November 2004, Nihon rinsho. Japanese journal of clinical medicine,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
May 1990, Chemical & pharmaceutical bulletin,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
January 1967, Biochimica et biophysica acta,
Huazhong Li, and Guangshan Zhao, and Hideo Miyake, and Hayato Umekawa, and Tetsuya Kimura, and Kunio Ohmiya, and Kazuo Sakka
July 2004, FEBS letters,
Copied contents to your clipboard!